EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Black Hole: CAR T Cell Therapy in AML

Erden Atilla iD, Karim Benabdellah iD

Cancers · 11.05.2023 · 15 (10) · 2713

DOI: 10.3390/cancers15102713 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 11.05.2023. Verfasst von Erden Atilla und 1 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Ave N, Seattle, WA 98109, USA. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite exhaustive studies, researchers have made little progress in the field of adoptive cellular therapies for relapsed/refractory acute myeloid leukemia (AML), unlike the notable uptake for B cell malignancies. Various single antigen-targeting chimeric antigen receptor (CAR) T cell Phase I trials have been established worldwide and have recruited approximately 100 patients. The high heterogeneity at the genetic and molecular levels within and between AML patients resembles a black hole: a great gravitational field that sucks in everything. One must consider the fact that only around 30% of patients show a response; there are, however, consequential off-tumor effects. It is obvious that a new point of view is needed to achieve more promising results. This review first introduces the unique therapeutic challenges of not only CAR T cells but also other adoptive cellular therapies in AML. Next, recent single-cell sequencing data for AML to assess somatically acquired alterations at the DNA, epigenetic, RNA, and protein levels are discussed to give a perspective on cellular heterogeneity, intercellular hierarchies, and the cellular ecosystem. Finally, promising novel strategies are summarized, including more sophisticated next-generation CAR T, TCR-T, and CAR NK therapies; the approaches with which to tailor the microenvironment and target neoantigens; and allogeneic approaches.

Schlagwörter

Stichwörter der Autor:innen

CAR NK cellsRNAseqT cell receptor T cellsacute myeloid leukemiacellular therapieschimeric antigen T cells

Autor:innen und Institutionen

  • Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Ave N, Seattle, WA 98109, USA.
  • GENYO Centre for Genomics and Oncological Research, Genomic Medicine Department, Pfizer/University of Granada/Andalusian Regional Government, Health Sciences Technology Park, 18016 Granada, Spain.

ORCID-Profile: Erden Atilla, Karim Benabdellah

Zitieren

APA

Atilla, E., & Benabdellah, K. (2023). The Black Hole: CAR T Cell Therapy in AML. Cancers, 15(10), 2713. https://doi.org/10.3390/cancers15102713

Vancouver

Atilla E, Benabdellah K. The Black Hole: CAR T Cell Therapy in AML. Cancers. 2023;15(10):2713. doi:10.3390/cancers15102713

BibTeX
@article{Atilla2023,
  author = {Atilla, Erden and Benabdellah, Karim},
  title = {The Black Hole: CAR T Cell Therapy in AML},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {10},
  pages = {2713},
  doi = {10.3390/cancers15102713}
}
Kostenlos starten →